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Introduction
Heart and cerebrovascular diseases have remained the major causes of death and disability in the United States (Heron, 2016; Mozaffarian et al., 2016) despite relentless efforts in cardiovascular research and drug development. Hypertension is a multifactorial disorder that places individuals at a higher risk for such diseases. Multiple genome-wide association studies (GWAS) have discovered polymorphisms in genes and loci that are associated with hypertension (Adeyemo et al., 2009; Dominiczak and Munroe, 2010; Franceschini et al., 2014; Huan et al., 2015; Levy et al., 2009; Lind and Chiu, 2013; Newton-Cheh et al., 2009; Pan et al., 2015) .
However, current knowledge about hypertension genetics is still far from complete. Common variants identified in GWAS only explain a small fraction of the blood pressure variance landscape (Dominiczak and Munroe, 2010) . This limitation highlights the need to study rare variants that may contribute to this complex disorder (Gibson, 2012; Schork et al., 2009 ).
G protein coupled receptors (GPCRs) play a critical role in vascular tone regulation (Brinks and Eckhart, 2010) . Several GPCRs with preferential activation of heterotrimeric G proteins of the Gαq family (e.g. Angiotensin II, Endothelin and α1 adrenergic receptors) mediate vasoconstrictor responses in blood vessels and many antihypertensive drugs act to counteract their effects.
Regulator of G protein signaling (RGS) proteins play a crucial role in modulating GPCR signaling through their GTPase-activating protein (GAP) activity toward Gα subunits. RGS2, in particular, has been strongly implicated in cardiovascular regulation due to its selectivity toward Gq, resulting in diminished vasoconstrictor action (Heximer et al., 1997) . Homozygous and heterozygous RGS2 knock out mice exhibit a hypertension phenotype attributed to prolonged Gq-mediated vasoconstrictor signaling (Heximer et al., 2003) and a reduced NO/cGMP-mediated vascular relaxation response (Sun et al., 2005; Tang et al., 2003) . Mice lacking RGS2 are also This article has not been copyedited and formatted. The final version may differ from this version.
Molecular Pharmacology Fast Forward. Published on August 7, 2017 as DOI: 10.1124 at ASPET Journals on August 11, 2017 molpharm.aspetjournals.org Downloaded from MOL #109215 5 prone to cardiac hypertrophy due to elevated Gq signalling (Zhang et al., 2006) . Increased sympathetic tone and altered renal mechanisms also contribute substantially to hypertension development in RGS2 knock-out mice (Gross et al., 2005; Gurley et al., 2010; Osei-Owusu et al., 2015) .
The actual role of RGS2 in human hypertension is not well understood. A number of common variants in the promoter, introns and noncoding regions of RGS2 gene are associated with hypertension and suboptimal responsiveness to anti-hypertensive treatment in different ethnic groups (Freson et al., 2007; Riddle et al., 2006; Semplicini et al., 2006; Yang et al., 2005; Zhang et al., 2013) . Several reported missense mutations in RGS2 were found predominantly in hypertensive subjects but with very low allele frequencies (Yang et al., 2005) . Among those, the Q2L mutant allele was shown to have low protein expression due to rapid proteasomal degradation (Bodenstein et al., 2007; Park et al., 2015) . The R44H mutant, on the other hand, showed less efficient plasma membrane targeting (Gu et al., 2008) . Since these missense mutations of RGS2 had such low allele frequencies (less than 1%), it has been difficult to determine the functional significance of these mutations using epidemiological or informatics approaches.
The revolution in next-generation sequencing has revealed genetic information useful for prevention and clinical management (Rabbani et al., 2014) . More commonly, healthcare professionals are presented with variants of uncertain significance (VUS), complicates the interpretation of genetic data (Ackerman, 2015; Gomez et al., 2016) . Computational tools have been developed to predict variant effects with limited success (Schulz et al., 2015) . Definitive characterization of VUS requires family segregation or functional studies. In alignment with this common theme, many missense mutations of RGS2 have been released to public databases such as NHLBI GO Exome Sequencing project (http://evs.gs.washington.edu/EVS/) and Exome This article has not been copyedited and formatted. The final version may differ from this version. Aggregation Consortium (ExAC -http://exac.broadinstitute.org) but the functional consequences and human phenotypes of these variants is largely unknown. We hypothesized that changes in the coding sequence of RGS2 may result in protein products that have altered function. In this study, we examined 16 mutations (Table 1) found in a Japanese population (Yang et al., 2005) , the NHLBI exome sequencing project (Fu et al., 2013) and the ExAC database (Lek et al., 2016) to determine whether they differ from WT RGS2 in their ability to regulate GPCR-mediated signalling. For those with reduced function, we determined the molecular characteristics contributing to those differences. Specifically, we investigated protein levels, protein localization and G protein binding activities of these mutants to further our understanding about the underlying mechanisms responsible for functional alteration of the mutants. Only a small fraction of variants showed altered function and it was due to several distinct mechanisms.
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Results
Differential effects of human RGS2 mutants to inhibit AT1 receptor-mediated intracellular calcium release
In the current study, we investigated the biochemical properties of 16 SNPs in the coding region of RGS2 previously identified in humans ( Figure 1A) . As an initial screen to determine the function of RGS2 mutants, CHO cells were co-transfected with cDNAs encoding AT1R (1 g)
and WT or mutant RGS2 (0.75µg). At this ratio, the suppression of AT1R-stimulated Ca 2+ release by RGS2 was sub-maximal, enabling the identification of both gain-and loss-of function mutations (Supplemental Fig. 2 ). In the absence of RGS2, AT1R stimulation by angiotensin II caused a rapid and transient peak of intracellular calcium [Ca 2+ ]i ( Fig. 1 B, C) .
obtained from the dose response curves in cells expressing receptor without RGS2 (Fig. 1 D, E) was set as 100%. WT RGS2 protein co-expression inhibits peak [Ca 2+ ]i by 48  2% (Fig. 1 B, Fig. 3 ). Four mutants including the Q2L, R188H, R44H and D40Y showed reduced function ( Fig. 1 C, E, F) . The 12 remaining mutants had comparable inhibitory effects to RGS2-WT. Therefore, they are considered to have normal function in this screen ( Fig. 1 B, D, F) . There was no significant change in EC50 mediated by RGS2 mutants compared to RGS2 WT (Supplemental table 1).
Transient protein expression levels of C-terminal V5 tagged RGS2
Differential protein expression could explain the different effects of these mutations. Specifically, the Q2L mutant has been shown to have low protein levels in HEK-293T (Bodenstein et al., 2007) and HeLa cells (Park et al., 2015) due to enhanced proteasomal degradation. In this study, we expressed C-terminal V5 tagged RGS2 WT and mutant constructs in CHO cells and total cell
This article has not been copyedited and formatted. The final version may differ from this version. 13 lysates were probed with V5 tag antibody using Western blot. Consistent with previous work, the Q2L protein levels were also low in CHO cells (60% reduction, p < 0.05, Fig. 2 ) due to rapid protein turnover (t1/2 Q2L: 6  1 min vs RGS2 WT: 17  4 min) (Supplemental Fig. 4) . None of the other 15 mutants showed low protein expression as compared to RGS2 WT (Fig. 2 ).
D40Y and R44H mutants are mis-localized
Two of the mutants with reduced function, D40Y and R44H, had disrupted plasma membrane (PM) localization (Fig. 3 ) This had previously been demonstrated for the R44H mutant (Gu et al., 2008) . In HEK-293 cells transfected with C-terminal GFP-tagged RGS2, nearly 100% localized in the nucleus when it was expressed alone ( Fig. 3 A, B, C, I ). Co-transfection with Gq Q209L induced 67% of WT RGS2 to translocate to the PM (Fig. 3 E, J, K). The Q2L mutant had a similar translocation level compared to RGS2 WT (Fig. 3 K) . The R44H mutant, as expected, had less protein localizing to the PM (21  2% less than WT RGS2, p < 0.0001, Fig. 3 G, J, K). The D40Y mutant was also less efficiently translocated with only 35% protein in the PM (32  2% less than RGS2 WT, p<0.0001, Fig. 3 F, J, K). A fraction of total R188H-GFP protein formed multiple aggregates throughout the cytoplasm either with or without Gαq Q209L co-expression (white arrow - Fig. 3 D, H ).
Biochemical characteristics of RGS2 mutants: RGS2-Gq binding and thermal stability
Among the 16 RGS2 mutants investigated, there are 4 mutations located in the RGS domain of RGS2: A99G, I110V, R188H and Q196R. Only the R188H mutant was identified as having reduced function. We hypothesized that that mutation could interfere with the binding of RGS2 The R188H mutant, on the other hand, had a much lower affinity (Ki 233 nM, Fig. 4A ).
We also measured the thermal stability of the R188H and Q196R mutants using differential scanning fluorimetry. Melting temperatures (Tm) of WT RGS2 and Q196R were similar, 46.8 and 49C, respectively. R188H had a significantly lower Tm at 40 C which reflects markedly lower protein stability (p < 0.001, Fig. 4B ). R188H also had significantly higher basal fluorescence, indicating a less stable protein (Supplemental Fig. 5 ). This measure of protein stability, however, did not correlate with protein stability in cells. The proteasome inhibitor MG-132 increased protein levels of R188H with a similar magnitude as that of RGS2 WT (Supplemental Fig.6 ).
Discussion
Over 70 rare non-synonymous RGS2 mutations have been identified in humans through multiple exome sequencing projects and these may contribute to a propensity for hypertension. Of these, 32 mutations are reported in at least 2 individuals, with the Q50K mutant having the highest allele frequency of 0.08% of overall population. Data are publicly available through The Exome Aggregation Consortium. In this study, we focused on 16 mutations (nonsynonymous polymorphisms) that were found in at least 2 individuals in both the ExAC and the NHLBI GO Exome Sequencing project databases. We identified 4 mutations that result in RGS2 proteins that display a functional deficit in inhibiting AT1R-mediated increases in intracellular calcium in CHO cells. Of these 4, the results with the D40Y and R188H mutants are novel while the Q2L and R44H
mutants have been investigated in the past. Lower basal protein expression, impaired plasma membrane targeting, and G protein binding deficiency were identified as the mechanisms most likely responsible for the reduced function of these mutants.
Multiple Gq coupled receptors have been used to probe RGS2 function in vitro such as M1 or M3 muscarinic receptors (Bodenstein et al., 2007; Gu et al., 2007; Gu et al., 2008) or the vasopressin receptor (Osei-Owusu et al., 2007) . In this study, we chose the angiotensin II receptor because of its relevance in systematic regulation of vascular function and blood pressure (Cameron et al., 2016; de Kloet et al., 2015; Li and Zhuo, 2016) . Moreover, RGS2 has been proposed to serve as a selective and potent regulator of AT1R, due to interaction through its amino terminal domains (Hercule et al., 2007; Heximer et al., 2003; Matsuzaki et al., 2011) . As 12 of the RGS2 mutations included in the study are located in the RGS2 amino terminal region (Fig. 1 A) , a functional screen against AT1R could reveal mutations that selectively disrupt RGS2 protein activity by blocking RGS2-receptor coupling. However, we did not find such mutants in our screen (Fig. 1 F) . We also This article has not been copyedited and formatted. The final version may differ from this version. did not identify any gain-of-function mutations, despite using conditions that would enable such identification (Supplemental Fig. 2 ).
Low expression of RGS2 protein resulting in prolonged GPCR signaling has been proposed for hypertension in the case of the rare Q2L missense mutation and the common C1114G polymorphism in the 3'-UTR of the RGS2 gene (Park et al., 2015; Semplicini et al., 2006) . We further confirmed that the Q2L mutant RGS2 has low protein expression (Fig. 2) due to a rapid turnover rate (Supplemental Fig. 4 A, C) . No other RGS2 mutants that we investigated had low cellular protein levels in our system (Fig. 2) .
The amphipathic  helix at the amino terminus of RGS2 promotes plasma membrane association and affects protein function (Gu et al., 2007) . The R44H mutation has been shown to impair RGS2 membrane targeting by interference with lipid bilayer association (Gu et al., 2008) .
In this study, we confirmed that effect of the R44H mutation (Fig. 3 C , G, J, K). We also identified another mutation in this  helix, D40Y, that exhibited reduced plasma membrane localization ( Fig. 3 B, F, J, K) and function ( Fig. 1 C, E, F) . Unlike the R44H mutant in which both residues have a positive charge, the amino acid substitution in D40Y changes from the negatively charged aspartic acid to the hydrophobic tyrosine residue. This more dramatic alteration could explain the somewhat larger effect on Gq-dependent membrane localization (R44H: 46% of control vs D40Y: 35%, Fig. 3 K) .
While protein expression levels and membrane localization indirectly affect the negative regulatory effects of RGS2 on Gq-coupled receptor signaling, the interaction between RGS2 and Gq protein is absolutely critical for RGS2 function. The published crystal structure of the RGS2
domain/Gq protein complex shows that the arginine residue at position 188 is close to the binding interface between two proteins (Nance et al., 2013) . It may also form networked salt bridges This article has not been copyedited and formatted. The final version may differ from this version. (Donald et al., 2011) with the glutamate residue at position 104 to stabilize protein tertiary structure (Fig. 4C ). When this arginine is mutated to a histidine residue, the histidine rotamer with the least steric hindrance may not be sufficiently close to E104 to form a salt bridge, potentially rendering RGS2 more flexible and less structurally stable (Fig. 4D) . Besides the lower melting temperature (Fig. 4B) , the initial fluorescence of the R188H mutant with the thermostability dye was noticeably higher than that of the WT and Q196R proteins (Supplemental Fig. 5 ). This suggests a disruption of basal protein folding. This misfolding could also explain the aggregation of the R188H-GFP in cells in the localization study. Disruption of the binding interface and structural instability properties of the R188H may explain the reduced binding affinity to Gq. Further investigation demonstrated that this mutant has slightly shorter half-life than WT RGS2 (16  1.5 min vs 22  1.3 min, N.S., Supplemental Fig. 3 B, D) and is also subjected to proteasomal degradation (Supplemental Fig. 6 ).
The regulatory function of RGS2 in cardiovascular homeostasis is not limited to its inhibitory effect toward Gq signaling. RGS2 can also control protein synthesis through interaction with the eukaryotic initiation factor, eIF2B which has been implicated in protection against cardiac hypertrophy (Chidiac et al., 2014; Nguyen et al., 2009) . RGS2 may also interact with Gs and several adenylate cyclase subtypes to decrease cAMP production in cell-based assays (Roy et al., 2006; Salim et al., 2003) . Overall, our study mainly focused on the canonical RGS2 effect to reduce Gq signaling. How RGS2 mutants function with respect to these other mechanisms has not been tested so the 12 mutants with "normal" function here may be perturbed in other ways.
Some common polymorphisms in regulatory regions of RGS2 gene such as in-del mutations in the 3' UTR have been shown to contribute to cardiovascular diseases such as This article has not been copyedited and formatted. The final version may differ from this version. hypertension and responsiveness to anti-hypertensive treatment (He et al., 2015; Kvehaugen et al., 2014; Riddle et al., 2006; Semplicini et al., 2006; Zhang et al., 2013) . In this study, we demonstrate that rare mutations in the protein coding region of RGS2 can affect protein function at least in 3 different ways (protein stability, localization, and G protein binding), and result in signaling deregulation. How the function of RGS2 mutants in vitro correlates with their activities in vascular tissue or in human physiology will need to be determined. The results from this study could guide the development RGS2 transgenic animal models to derive further knowledge about the activity of rare RGS2 mutations in vivo. It will also provide a strategy to selectively target these mechanisms with directed repurposed or novel cardiovascular therapeutics.
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